date:Feb 16, 2013
id bacteria.
For the production of probiotics, CSL has a GMP pharmaceutical approved facility. Together with CSL, Clerici-Sacco therefore believes that it gains a great opportunity to consolidate its strategic penetration into the pharmaceutical/nutraceutical segment on a global scale.
Synergistic effects will also come through merging and simplifying the two culture portfolios into one, said Martino Verga, CSO. And, naturally, there will be benefits by changing over to the most optimized pro